|
Drugs. Mycophenolate mofetil (CellCept), a newer drug, is proving to be helpful in treating kidney disease associated with SLE and has fewer side effects than other immunosuppressants. It is taken by mouth. Recent studies suggest that it works better than cyclophosphamide. CellCept may be best for patients with mild to moderate lupus kidney disease and may not be appropriate for patients with advanced kidney disease.
Text Continues Below

Intravenous cyclophosphamide is the most effective drug at this time for proliferative lupus nephritis, and, in combination with a steroid, has been shown to control advanced kidney disease in between 60 - 90% of patients. It has severe side effects including nausea, vomiting, hair loss, and infertility.
Steroids are also useful for treating active kidney disease and for managing milder forms of nephritis.
Procedures. Kidney transplant or dialysis should be considered for patients with SLE with severe kidney damage. For unknown reasons, SLE does not generally recur in the transplanted kidneys. Studies are conflicting, however, over whether SLE transplant patients have higher organ-rejection rates than other kidney-transplant recipients. Both transplantation and dialysis have potentially serious complications.
Plasmapheresis. It is not clear if plasmapheresis is beneficial for SLE kidney disease.
|